The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research

Oncologist. 2023 Aug 3;28(8):657-663. doi: 10.1093/oncolo/oyad110.

Abstract

In May 2019, the US Food and Drug Administration (FDA) released the Framework for FDA's Real-World Evidence (RWE) Program, a draft guidance to evaluate the potential use of real-world data in facilitating regulatory decisions. As a result, pharmaceutical companies and medical communities see patient registries, which are large, prospective, noninterventional cohort studies, as becoming increasingly important in providing evidence of treatment effectiveness and safety in clinical practice. Patient registries are designed to collect longitudinal clinical data on a broad population to address critical medical questions over time. With their large sample sizes and broad inclusion criteria, patient registries are often used to generate RWE in the general and underrepresented patient populations that are less likely to be studied in controlled clinical trials. Here, we describe the value of industry-sponsored patient registries in oncology/hematology settings to healthcare stakeholders, in drug development, and in fostering scientific collaboration.

Keywords: observational study; oncology; prospective cohort study; real-world evidence; registry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Industry*
  • Humans
  • Prospective Studies
  • Registries
  • Treatment Outcome